Immune Modulation for Enzyme Replacement Therapy in A Female Patient With Hunter Syndrome
Open Access
- 21 May 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 1000
- https://doi.org/10.3389/fimmu.2020.01000
Abstract
A 3.5 year old Hispanic female presented with signs and symptoms concerning for MPS II (Hunter Syndrome). The diagnosis of MPS II was confirmed by enzyme and molecular testing. Genetic evaluation revealed undetectable plasma iduronate-2-sulfatase enzyme activity and an inversion between intron 7 of the IDS gene and a region near exon 3 of IDS-2. This inversion is the molecular cause for ~8% of cases of MPS II and often results in a severe phenotype. X-inactivation studies revealed an inactivation ratio of 100:0. Given the patient's undetectable enzyme level, in combination with a severe IDS gene mutation, classic features at time of presentation, and the significantly skewed X inactivation, there was concern that she was at high risk of developing high and sustained antibody titers to idursulfase which would limit her benefit from enzyme replacement therapy (ERT). Anti-drug neutralizing antibodies to idursulfase have been associated with reduced systemic exposure to idursulfase and poorer clinical outcomes. Therefore, the decision was made to concurrently treat the patient with immune tolerance induction therapy during the first month of treatment with idursulfase in order to decrease the risk of developing high sustained antibody titers. The immune tolerance induction protocol consisted of rituximab weekly for 4 weeks, methotrexate three times a week for 3 weeks and monthly IVIG through B-cell and immunoglobulin recovery. Immune tolerance induction was initiated concurrently with the start of ERT. The patient had no significant adverse effects related to undergoing immune tolerance induction therapy and two and half years later is doing well with significantly reduced urine glycosaminoglycans and very low anti-drug antibody titers. This immune tolerance induction protocol could be considered for other patients with MPS II as well as patients with other lysosomal storage disorders who are starting on enzyme replacement therapy and are at high risk of developing neutralizing anti-drug antibodies.Keywords
This publication has 35 references indexed in Scilit:
- Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and FutureTransplantation and Cellular Therapy, 2019
- Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence reviewGenetics in Medicine, 2017
- Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: A case reportMolecular Genetics and Metabolism, 2017
- Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)Orphanet Journal of Rare Diseases, 2015
- Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type IIMolecular Genetics and Metabolism Reports, 2014
- Mucopolysaccharidosis type II in a female patient with a reciprocal X;9 translocation and skewed X chromosome inactivationAmerican Journal of Medical Genetics Part A, 2014
- The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5years and older treated with intravenous idursulfaseMolecular Genetics and Metabolism, 2013
- Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe diseaseGenetics in Medicine, 2012
- Umbilical cord blood transplantation for non-malignant diseasesBone Marrow Transplantation, 2009
- Recognition and Diagnosis of Mucopolysaccharidosis II (Hunter Syndrome)PEDIATRICS, 2008